Fominoben

Fominoben
Clinical data
Trade names	Broncomenal, Deronyl, Finaten, Noleptan, Oleptan, Terion, Tosifar, Tussirama
Identifiers
	IUPAC name N-[3-chloro-2-[[methyl-(2-morpholin-4-yl-2-oxoethyl)amino]methyl]phenyl]benzamide;
CAS Number	18053-31-1 ;
PubChem CID	3407;
DrugBank	DB08968;
ChemSpider	3290;
UNII	TJ2KK6NYJS;
KEGG	D07988;
ChEBI	CHEBI:135639;
ChEMBL	ChEMBL1697837;
CompTox Dashboard (EPA)	DTXSID1023075 ;
ECHA InfoCard	100.038.135
Chemical and physical data
Formula	C21H24ClN3O3
Molar mass	401.89 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CC1=C(C=CC=C1Cl)NC(=O)C2=CC=CC=C2)CC(=O)N3CCOCC3;
	InChI InChI=1S/C21H24ClN3O3/c1-24(15-20(26)25-10-12-28-13-11-25)14-17-18(22)8-5-9-19(17)23-21(27)16-6-3-2-4-7-16/h2-9H,10-15H2,1H3,(H,23,27); Key:KSNNEUZOAFRTDS-UHFFFAOYSA-N;

Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan.^[2] It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives.^[3] It is reported to have respiratory stimulant activity.^[4] Other research has indicated it may be an agonist at the benzodiazepine site of the GABA_A receptor.^[5] It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983.^[6]

Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria.^[7]

References

^ Swiss Pharmaceutial Society, ed. (January 2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 470. ISBN 978-3-88763-075-1.
^ "FOMINOBEN". NCATS Inxight: Drugs. Retrieved March 25, 2021.
^ Musacchio JM, Klein M (June 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–56. doi:10.1007/BF00711241. PMID 3044591. S2CID 33844132.
^ Sasaki T, Sugiyama M, Sasaki H, Suzuki S, Takishima T (1985). "Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method". The Journal of International Medical Research. 13 (2): 96–101. doi:10.1177/030006058501300204. PMID 3158563. S2CID 30176251.
^ Crawley JN, Blumstein LK, Baldino F (January 1984). "Anxiolytic-like properties of fominoben". European Journal of Pharmacology. 97 (3–4): 277–81. doi:10.1016/0014-2999(84)90460-6. PMID 6142823.
^ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1705–7. ISBN 978-0-8155-1856-3.
^ Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN 9788448604271.

[1] Swiss Pharmaceutial Society, ed. (January 2000). Index Nominum 2000: International Drug Directory. Taylor & Francis. p. 470. ISBN 978-3-88763-075-1.

[2] "FOMINOBEN". NCATS Inxight: Drugs. Retrieved March 25, 2021.

[3] Musacchio JM, Klein M (June 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–56. doi:10.1007/BF00711241. PMID 3044591. S2CID 33844132.

[4] Sasaki T, Sugiyama M, Sasaki H, Suzuki S, Takishima T (1985). "Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method". The Journal of International Medical Research. 13 (2): 96–101. doi:10.1177/030006058501300204. PMID 3158563. S2CID 30176251.

[5] Crawley JN, Blumstein LK, Baldino F (January 1984). "Anxiolytic-like properties of fominoben". European Journal of Pharmacology. 97 (3–4): 277–81. doi:10.1016/0014-2999(84)90460-6. PMID 6142823.

[6] William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 1705–7. ISBN 978-0-8155-1856-3.

[7] Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN 9788448604271.

[2]

[3]

[4]

[5]

[6]

[1]

[7]